矮小症应用重组人生长激素治疗的效果及安全性分析  

Efficacy and safety of recombinant human growth hormone therapy for dwarfism

作　　者：董超凡 Dong Chaofan(Department of Pediatric Internal Medicine,Jingdezhen First People's Hospital,Jingdezhen,Jiangxi,333000,China)

机构地区：[1]景德镇市第一人民医院儿内科

出　　处：《当代医学》2019年第27期12-14,共3页Contemporary Medicine

摘　　要：目的探讨重组人生长激素用于治疗矮小症的疗效及安全性。方法随机选取本院于2015年8月至2018年8月间收治的80例特发性矮小症及生长激素缺乏症患儿,对其均应用重组人生长激素治疗,其中32例特发性矮小症患儿纳入对照组,余下48例生长激素缺乏症患儿纳入观察组。结果经治疗后,两组患儿身高、骨龄、体质量及生长速度等均比治疗前有明显提高,其中生长速度比较,差异有统计学意义(P<0.05);治疗后,两组患儿血糖、甲状腺功能均处于正常范围,差异无统计学意义;治疗后,两组患儿血清IGF-1浓度与治疗前相比有明显提高,差异有统计学意义(P<0.05)。治疗后,两组患儿治疗后3个月身高、骨龄、体质量、生长速度、血糖、甲状腺功能及血清IGF-1浓度比较,差异有统计学意义(P<0.05);两组患儿治疗后6个月各项指标差异无统计学意义。结论将重组人生长激素用于治疗特发性矮小症与生长激素缺乏症,不仅临床疗效较佳,且安全性较高,值得临床推广。Objective To investigate the efficacy and safety of recombinant human growth hormone(hGH)in the treatment of short stature.Methods 80 children with idiopathic short stature and growth hormone deficiency admitted to our hospital from August 2015 to August 2018 were randomly selected and treated with recombinant human growth hormone.Among them,32 children with idiopathic short stature were included in the control group and the remaining 48 children with growth hormone deficiency were included in the observation group.Results The height,bone age,body mass and growth rate of the two groups were significantly higher than those before treatment,and there was significant difference in growth rate(P<0.05);after treatment,blood sugar and thyroid function of the two groups were in the normal range,with no significant difference;after treatment,there was no significant difference in blood sugar and thyroid function between the two groups.The serum levels of IGF-1 in the two groups were significantly higher than those before treatment(P<0.05).After treatment,the height,bone age,body weight,growth rate,blood glucose,thyroid function and serum IGF-1 concentration in the two groups were statistically significant(P<0.05);There was no significant difference in the indicators between the last 6 months.Conclusion Recombinant human growth hormone is effective and safe in the treatment of idiopathic short stature and growth hormone deficiency,which is worthy of clinical promotion.

关 键 词：特发性矮小症 生长激素缺乏矮小症 重组人生长激素 疗效 安全性 

分 类 号：R72[医药卫生—儿科]